Decoy Therapeutics Partners with hVIVO for Phase 1b Study of D-MAV™ Against Respiratory Virus

Decoy Therapeutics is collaborating with hVIVO to propel their lead drug candidate, D-MAV, into clinical trials. The partnership aims to evaluate the safety and efficacy of D-MAV in a controlled human challenge study, marking a significant step forward in its development.

Under the agreement, hVIVO will conduct a Phase 1b study to assess D-MAV’s ability to combat a specific respiratory virus. The study will involve healthy volunteers who will be exposed to the virus under controlled conditions. Researchers will then monitor the drug’s impact on viral load, symptom severity, and immune response. Decoy Therapeutics anticipates that the data collected from this study will provide valuable insights into D-MAV’s potential as a novel therapeutic intervention for respiratory infections.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI